Compare McKesson Corporation (MCK) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Vistra Corp — how do they compare? McKesson Corporation trades at $884.59 (market cap $105.14B), while Vistra Corp trades at $146.3 (market cap $48.64B). The key difference: McKesson Corporation is far larger — about 2.2× Vistra Corp's market cap, and Vistra Corp pays the higher dividend (0.63%). Which is the better fit depends on your goals.
| MCK | VST | |
|---|---|---|
Market Cap | $105.14B | $48.64B |
Sector | Health | Technology |
52-Week High | $995.69 | $217.92 |
52-Week Low | $659.01 | $134.71 |
Enterprise Value | $111.67B | $70.58B |
Dividend Yield | 0.42% | 0.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $889.01, up 1.04% today, with a bullish technical outlook and strong institutional support. Recent Q1 2027 earnings beat expectations, with EPS of $9.93 versus $9.56, driven by specialty drug growth and oncology performance. Revenue reached $359.05B in 2025, with net income of $3.30B, though margins remain thin. The company raised full-year guidance, reflecting operational momentum.
The stock offers upside to the consensus price target of $990.67, supported by 80% analyst buy ratings. Key risks include reliance on pharmaceutical distribution margins, regulatory pressures, and competitive threats. Earnings consistency and cost discipline are critical for sustaining valuation multiples amid healthcare sector volatility.
VST trades at $146.36, up 2.44% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings with $1.767 billion adjusted EBITDA, beating expectations, while maintaining 2026 guidance. Valuation metrics show a P/E of 24.44 and robust profitability with 75.73% ROE, though recent earnings have been inconsistent with two misses in the last four quarters.
VST presents a compelling growth story driven by data center power demand and nuclear assets, with 90.9% analyst buy ratings and a $239.75 price target suggesting 64% upside. Key risks include ERCOT pricing volatility and hedging losses, while institutional interest remains strong with recent strategic acquisitions positioning the company for AI infrastructure growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
